Current health news briefs cover potential risks linked to Novo Nordisk's diabetes drug Ozempic, opposition to Robert F.
Novo Holdings, parent company of the pharmaceutical giant Novo Nordisk, is spending $16.5 billion on the acquisition. It will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback